Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-α for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis

Scandinavian Journal of Gastroenterology

Volumn 44, Issue 12, 2009, Pages 1477-1486

  Eun, Jong Ryul ^a   Lee, Heon Ju ^a   Moon, Hee Jung ^a   Kim, Tae Nyeun ^a   Kim, Jae Woon ^a   Chang, Jay Chun ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

5 fluorouracil; Cisplatin; Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Interferon

Indexed keywords

ALPHA INTERFERON; CISPLATIN; FLUOROURACIL; INTERMAX ALPHA; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRCULATION; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN; PRIORITY JOURNAL; THROMBOSIS; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRA-ARTERIAL; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM STAGING; PORTAL VEIN; PROGNOSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 72449142264     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365520903367262     Document Type: Article

References (36)

1. Shiratori Y, Yoshida H, Omata M. Management of hepatocellular carcinoma: Advances in diagnosis, treatment and prevention. Anticancer Ther 2001;1:277-90.
2. Boring CC, Squires TS, Tong T. Cancer statistics. CA Cancer J Clin 1992;42:19-38.
3. Sandhu DS, Tharayil VS, Lai JP, Roberts LR. Treatment options for hepatocellular carcinoma. Exp Rev Gastroenterol Hepatol 2008;2:81-92.
4. Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2006;106: 1990-7.
5. Toyosaka A, Okamoto E, Mitsunobu M, Oriyama T, Nakao N, Miura K. Intrahepatic metastasis in hepatocellular carcinoma: Evidence for spread via the portal vein as an efferent vessel. A Am J Roentgenol 1996;91:1610-15. (Pubitemid 26269180)
6. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 1990;211:277-87.
7. Doci R, Bigami P, Bozzetti F, Bonfanti G, Audisio R, Colombo M, et al. Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 1988;61:1983-7.
8. Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997;79:1980-6.
9. Ando E, Tanaka MT, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases. Cancer 2002;95:588-95.
10. Lai YC, Shin CY, Jeng CM, Yang SS, Hu JT, Sung YC, et al. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with tumor thrombosis of the portal vein. World J Gastroenterol 2003;9:2666-70.
11. Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998;55:39-47.
12. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002;94:435-42. (Pubitemid 34081374)
13. Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-a and intra-arterial 5-fluorouracil; role of type I interferon receptor expression. Br J Cancer 2005;93:557-64.
14. Hamabe ST, Yamasaki T, Saeki I, Harima Y, Okita K, Terai S, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: Is the addition of subcutanesous interferon-a-2b beneficial? Hepatol Res 2009;39:223-30.
15. Stehlim JS Jr, de Ipolyi PD, Greeff PJ, McGaff CJ Jr, Davis BR, McNary L. Treatment of cancer of the liver. Twenty years' experience with infusion and resection in 414 patients. Ann Surg 1988;208:23-35.
16. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, et al. The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 1995;52:285-99.
17. Hamada A, Yamakado K, Nakatsuka A, Takaki H, Akeboshi M, Takeda K. Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: Prognostic factors. J Vasc Intervent Radiol 2004;15:835-41.
18. Itamoto T, Nakahara H, Tashiro H, Haruta N, Asahara T, Naito A, et al. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with portal vein thrombus of the portal vein. J Surg Oncol 2002;80:143-8.
19. Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003;23:1891-8.
20. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:49-55.
21. Taniguchi K, Nakata K, Kato Y, Sato Y, Hamasaki K, Tsuruta S, et al. Treatment of hepatocellular carcinoma with transcatheter arterial embolization. Analysis of prognostic factors. Cancer 1994;73:1341-5.
22. Akashi Y, Koreeda C, Enomoto S, Uchiyama S, Mizuno T, Shiozaki Y, et al. Prognosis of unresectable hepatocellular carcinoma: An evaluation based on multivariate analysis of 90 cases. Hepatology 1991;14:262-8.
23. Okada S. Treanscatheter arterial embolization for advanced hepatocellular carcinoma: The controversy continues. Hepatology 1998;27:1743-4.
24. Leung TW, Johnson PJ. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001;28:514-20.
25. Lopez PM, Villanueva A, Llovet JM. Systemic review: Evidence- based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-47.
26. Aebersold DM. Potential and future strategies for radiotherapy in hepatocellular carcinoma. Liver Int 2009;29:145-6.
27. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
28. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 2006;12:7561-7.
29. Sausville EA, Longo DL Principles of cancer treatment. In: Braunwald E, Fauci AS, Dasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine, 15th ed. New York: McGraw-Hill; 2001. p. 542.
30. Scanlon KJ, Newman EM, Lu Y, Priset DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986;83:8923-5.
31. LoRusso P, Pazdur R, Redman BG, Kinzie J, Vaitkevicius V. Low-dose continuous infusion in advanced colorectal carcinoma. Am J Clin Oncol 1989;12:486-90.
32. Shwartz EL, Hoffman M, O'Connor CJ, Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon alpha in human colon carcinoma cells. Biochem Biopys Res Commun 1992;323:425-8.
33. Eguchi H, Nagano H, Yamamoto H, Miyamoto A, Kondo M, Dono K, et al. Augmentation of antitumor activity of 5-fluorouracil by interferon a is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 2000;6:2881-90.
34. Kondo M, Nagano H, Wada H, Damdinsuren B, Yamamoto H, Hiraoka N, et al. Combination of IFN-a and 5-fluorouracil induces apoptosis through IFN-a/b receptor in human hepatocellular carcinoma cells. Clin Cancer Res 2005;11:1277-86.
35. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. Integration of interferon-alpha/beta signally to P53 responses in tumor suppression and antiviral defense. Nature 2003;424:516-23.
36. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: Efficacy, side effects, and complications. Gut 2006;55:1350-9.